GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

GlaxoSmithKline's consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the drugmaker. The name of the ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

À LIRE AUSSI Unilever attaqué de toutes parts après son OPA ratée sur GSK Consumer Healthcare Tout le monde sur le pont pour augmenter la production de médicaments Pour augmenter la ...

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Dec 20 (Reuters) - GSK (GSK.L), opens new tab said on Friday ... company 10:54 PM UTC · Updated ago Healthcare & Pharmaceuticalscategory E-sellers of compounded weight-loss drugs fail to reveal ...

A pat­ent dis­pute between GSK sub­si­di­ary ViiV Health­care and Colom­bian reg­u­lat­ors is not cur­rently before the Inter­na­tional Centre for Set­tle­ment of Invest­ment Dis ...

GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare Conference, the European healthcare giant noted there ...